Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1995 1
1998 1
2006 2
2007 3
2008 7
2009 8
2010 5
2011 10
2012 7
2013 9
2014 16
2015 18
2016 18
2017 20
2018 24
2019 33
2020 28
2021 34
2022 27
2023 26
2024 31
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Schaeffer EM, et al. Among authors: lotan t. J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050. J Natl Compr Canc Netw. 2023. PMID: 37856213
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA. Schaeffer EM, et al. Among authors: lotan t. J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019. J Natl Compr Canc Netw. 2024. PMID: 38626801
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. Schaeffer EM, et al. Among authors: lotan t. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063. J Natl Compr Canc Netw. 2022. PMID: 36509074
A PRC2-independent function for EZH2 in regulating rRNA 2'-O methylation and IRES-dependent translation.
Yi Y, Li Y, Meng Q, Li Q, Li F, Lu B, Shen J, Fazli L, Zhao D, Li C, Jiang W, Wang R, Liu Q, Szczepanski A, Li Q, Qin W, Weiner AB, Lotan TL, Ji Z, Kalantry S, Wang L, Schaeffer EM, Niu H, Dong X, Zhao W, Chen K, Cao Q. Yi Y, et al. Among authors: lotan tl. Nat Cell Biol. 2021 Apr;23(4):341-354. doi: 10.1038/s41556-021-00653-6. Epub 2021 Apr 1. Nat Cell Biol. 2021. PMID: 33795875 Free PMC article.
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, Fields PA, Hu S, Denmeade SR, Pienta KJ, Pavlovich CP, Ross AE, Drake CG, Pardoll DM, Antonarakis ES. Shenderov E, et al. Among authors: lotan tl. Nat Med. 2023 Apr;29(4):888-897. doi: 10.1038/s41591-023-02284-w. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012549 Free PMC article. Clinical Trial.
The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong Q, Kryvenko ON, Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Trpkov K. Epstein JI, et al. Among authors: lotan t. Arch Pathol Lab Med. 2021 Apr 1;145(4):461-493. doi: 10.5858/arpa.2020-0015-RA. Arch Pathol Lab Med. 2021. PMID: 32589068 Free article. Review.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. Among authors: lotan tl. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
TFE3 -Rearranged PEComa/PEComa-like Neoplasms : Report of 25 New Cases Expanding the Clinicopathologic Spectrum and Highlighting its Association With Prior Exposure to Chemotherapy.
Argani P, Gross JM, Baraban E, Rooper LM, Chen S, Lin MT, Gocke C, Agaimy A, Lotan T, Suurmeijer AJH, Antonescu CR. Argani P, et al. Among authors: lotan t. Am J Surg Pathol. 2024 Jul 1;48(7):777-789. doi: 10.1097/PAS.0000000000002218. Epub 2024 Apr 10. Am J Surg Pathol. 2024. PMID: 38597260 Free PMC article. Review.
297 results